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Background: Aldo-keto reductase family 1 member C3 (AKR1C3) is a key steroidogenic enzyme that is overexpressed
in prostate cancer (PCa) and is associated with the development of castration-resistant prostate cancer (CRPC). The aim
of this study was to investigate the correlation between the expression level of AKR1C3 and the progression of PCa.
Methods: Sixty human prostate needle biopsy tissue specimens and ten LNCaP xenografts from intact or castrated
male mice were included in the study. The relationship between the level of AKR1C3 expression by
immunohistochemistry and evaluation factors for PCa progression, including prostate-specific antigen (PSA), Gleason
score (GS) and age, were analyzed.
Results: Low immunoreactivity of AKR1C3 was detected in normal prostate epithelium, benign prostatic hyperplasia
(BPH) and prostatic intraepithelial neoplasia (PIN). Positive staining was gradually increased with an elevated GS in PCa
epithelium and LNCaP xenografts in mice after castration. The Spearman’s r values (rs) of AKR1C3 to GS and PSA levels
were 0.396 (P = 0.025) and −0.377 (P = 0.036), respectively, in PCa biopsies. The rs of AKR1C3 to age was 0.76 (P = 0.011).
No statistically significant difference was found with other variables.
Conclusion: Our study suggests that the level of AKR.
1C3 expression is positively correlated with an elevated GS, indicating that AKR1C3 can serve as a promising biomarker
for the progression of PCa.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
7748245591110149.
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Prostate cancer (PCa) is the second most frequently diag-
nosed cancer and the sixth leading cause of cancer-related
mortality in men worldwide [1]. Androgen deprivation ther-
apy (ADT) is a mainstay treatment for metastatic prostate
cancer and is initially effective, with an 80-90% remission
rate in patients and improved overall survival. However,
most of the patients inevitably progress to CRPC [2,3]. Un-
fortunately, the median overall survival rate of CRPC is 23
to 37 months from the time of initiation of ADT [4]. Al-
though the definitive mechanism underlying the progres-
sion of PCa remains poorly understood, two major
mechanisms that result in the reactivation of the androgen* Correspondence: liyi@jlu.edu.cn; lijing@jlu.edu.cn
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unless otherwise stated.axis in CRPC have been extensively studied [5]. One is the
activation of the androgen receptor (AR)-mediated signal-
ing pathway either by the amplification, overexpression or
mutations of the AR [6,7]. The other mechanism mediates
intratumoral androgen synthesis, involving either the de
novo synthesis of AR ligands from cholesterol or the in-
creased conversion of adrenal androgens (e.g., dehydroepi-
androsterone or Δ4-Adione) to active androgens [8,9].
Based on the new theory of intratumoral androgen
synthesis in prostate cancer cells, AKR1C3 was found to
play a pivotal role in the synthesis of testosterone (T)
and dihydrotestosterone (DHT), which are the most ro-
bust stimuli for activation of the growth, proliferation
and metastasis of prostate cancer cells. In vitro experi-
ments have shown that AKR1C3 is up-regulated in pros-
tate cancer cells as a survival adaptation in response to
T/DHT deprivation [9]. The overexpression of AKR1C3. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Clinicopathological features of prostatic needle
biopsy samples
Sample Case number Mean age (Range) Mean PSA (Range)
BPH 10 64 (41–72) 13.7 (3.8-30.1)
PIN 10 84 (81–87) 18.1 (12.2-24)
GS = 6 10 69 (59–81) 52.7 (20.4-80.6)
GS = 7 10 69 (58–60) 57.9 (9.4-169)
GS = 8 10 70 (69–87) 59.8 (28–100)
GS = 9 10 70 (54–85) 71.2 (10–108.2)
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tosterone from 4-androstene-3,17-dione in LNCaP cells
and resulted in resistance to the 5α-reductase inhibitor
finasteride [10]. Dozmorov et al. demonstrated that the
overexpression of AKR1C3 promotes angiogenesis and
aggressiveness in PC-3 cells [11]. Several studies have re-
ported low or undetectable levels of AKR1C3 in normal
prostate epithelia, whereas elevated AKR1C3 levels have
been found in localized, advanced or recurrent PCa and
CRPC [12,13]. However, the correlation between the
expression levels of AKR1C3 and the progression of
PCa is unclear.
Recently, the benefit of prostate specific antigen (PSA)
in the diagnosis and treatment of PCa in men was doubted
by some researchers because PSA testing is associated with
modest reductions in prostate cancer mortality, over diag-
nosis and over treatment [14]. Therefore, the next gener-
ation of PCa biomarkers that are superior to PSA or
complement PSA testing should be explored. In our study,
60 human prostate needle biopsy tissue specimens and 10
murine tumor tissue specimens from intact or castrated
male nu/nu mice were selected to detect AKR1C3 expres-
sion levels. The relationship between the levels of AKR1C3
expression and factors evaluated for PCa progression, in-
cluding PSA, Gleason score (GS) and age, were analyzed,
aiming to investigate whether AKR1C3 may serve as a po-
tential biomarker for the progression of PCa.
Materials and methods
Patients and tissue samples
The PCa screening samples were obtained from 2001–
2009 in the Prostate Diseases Prevention and Treatment
Research Center of Jilin University in Changchun, Jilin
province, China. None of the patients had previously un-
dergone radical prostatectomy or other treatments, such as
hormone or radiotherapy. In this study, 60 biopsies were
selected for the assessment of AKR1C3 expression by im-
munohistochemistry staining. PCa case inclusion criteria
were designated as follows: (1) detection of cancer within
each prostate biopsy specimen, (2) GS of the biopsies equal
to or greater than 6, and (3) adenocarcinoma specimens
only. The clinicopathological features of PCa samples are
summarized in Table 1. This study was approved by the
Ethics Committee of Jilin University. The pathological diag-
noses were determined by an experienced urological
pathologist.
Cell culture and replication of LNCaP xenografts in mice
Human prostate LNCaP cells were obtained from the
American Type Culture Collection at Passage 4. LNCaP
cells were maintained in RPMI 1640 medium supple-
mented with 10% FBS, 2 mmol/L glutamine, 100 Units/
mL penicillin and 100 μg/mL streptomycin. LNCaP cells
(4 × 106) were collected in 70 μL PBS and mixed with70 μL Matrigel Matrix (Becton Dickinson Biosciences).
The mixture was injected subcutaneously on one side of
the dorsal flank of 6- to 7-week-old male nu/nu mice
(National Cancer Institute, Frederick, MD). When the
tumor volumes reached 100 mm3, the mice were random-
ized into a sham-operated group (n = 5) and a castrated
group (n = 5). Briefly, after the intramuscular injection of
general anesthesia with ketamine and xylazine (8.7 mg/
100 g and 1.3 mg/100 g body weight, respectively) and the
application of 75% alcohol to disinfect the scrotum, a
small midline incision was made to expose the testes. The
spermatic vessels were tied with 4.0 silk sutures, and the
testes were removed. The incision was then closed using
4.0 silk sutures. In sham-operated mice, the skin of the
scrotum was incised to expose the testes, followed only by
closure of the incision using sutures. The animals were
sacrificed at 3 weeks after the initial operation.
Antibodies
Primary antibodies included AKR1C3 (NP6.G6.A6, mouse
monoclonal antibody, 1:150, Abcam) and β-actin (mouse
polyclonal antibody, 1:1000, Santa Cruz). Secondary anti-
bodies were anti-mouse IgG (1:2000, Proteintech Group).
Immunohistochemistry
Prostate tissue specimens were cut into approximately
4–6-μm-thick sections, mounted and baked at 55°C over-
night. The sections were deparaffinized with xylene and
re-hydrated in graded ethanol. Endogenous peroxidase ac-
tivity was blocked by incubating the slides with 0.5% H2O2
in methanol for 10 min. Antigen retrieval was performed
by heating the slides in 10 mM citric acid buffer (pH 6.0)
at 121°C for 15 min in an autoclave. The slides were then
washed with 0.1 M Tris–HCl at pH 7.6 (Tris) for 5 min
and then incubated with Tris containing 10% goat serum
to block non-specific binding. Next, the slides were incu-
bated with AKR1C3 mAb (NP6.G6.A6, mouse monoclo-
nal antibody, 1:150, Abcam) at a dilution of 1:200 at 4°C
overnight. After washing with Tris, the slides were incu-
bated with biotinylated goat anti-mouse secondary anti-
body (1:2000, Proteintech Group) in Tris containing 10%
goat serum at room temperature for 1 h. Following the
washes with Tris, HRP-conjugated streptavidin diluted in
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which were incubated at room temperature for an add-
itional 40 min. After a 10-min wash in Tris, a DAB-H2O2
substrate was added to the slides and incubated at room
temperature for 6 min. The slides were then washed with
distilled water and counterstained with hematoxylin. Next,
the slides were dehydrated and sealed with Permount
Mounting Media for subsequent visualization. The nega-
tive controls were handled in the same way except that
PBS was applied in place of primary antibody.
AKR1C3 positive-staining exhibits a brown cytoplas-
mic and/or nuclear stain. Images of AKR1C3-positive
cells were acquired from five randomly chosen fields
(400×, magnification) per tissue section. The positive cell
density was assessed using Image-Pro Plus 6.0 software
(Media Cybernetics, Bethesda, MD, United States), and
the results are presented as mean optical density (MOD)
values. The negative controls were handled in the same
way except that PBS was applied in place of a primary
antibody.
Statistical analyses
All of the results were analyzed using SPSS software,
version 19.0 for Windows (SPSS Inc., IL, USA). One-way
ANOVA was used to examine mean differences between
groups. The data were recorded as the mean values ±
standard deviation (SD). The Spearman’s Rho was applied
to test for significant correlations between the variables.
P values < 0.05 were considered as statistically significant.
Results
The expression of AKR1C3 in human prostate needle
biopsy samples
In this study, immunohistochemical staining for AKR1C3
in human prostate needle biopsy tissue specimens, includ-
ing BPH, PIN and PCa, was carried out. Tissue sections
that are representative of the immunohistochemical stain-
ing with monoclonal anti-AKR1C3 antibody are shown in
Figure 1. In contrast to the negative staining observed in
the normal glandular epithelium specimen (characterized
by the small nuclei, Figure 1A) and the PBS control
(Figure 1D), a few disseminated cells with brown positive
immunoreactivity were visualized in the BPH (Figure 1B)
as well as in the PIN samples (Figure 1C). Positive cyto-
plasmic staining was widely observed in the prostate can-
cer cells (characterized by the larger nuclei) (Figure 1E-H).
The distribution of AKR1C3 expression is different be-
tween BPH and PCa. For BPH and PIN specimens, posi-
tive expression of AKR1C3 was observed in the stromal
cells other than the epithelial cells, and for malignant
prostate cancer specimens with GS greater than 6, a grad-
ually stronger positive staining of AKR1C3 was detected
in prostate cancer epithelial cytoplasm. The data also
showed that AKR1C3 expression gradually increased withincreasing GS (rs = 0.396, P = 0.025) and slightly increased
with age in BPH (rs = 0.76, P = 0.011), but the MOD for
positive AKR1C3 expression in prostate tumor tissues was
significantly higher than that of the BPH specimens. This
result implicated that the levels of AKR1C3 are closely as-
sociated with the PCa and GS.
The expression of AKR1C3 in castrated mouse prostate
cancer models
To further confirm the relationship between the progres-
sion of PCa and the expression of AKR1C3, the LNCaP
mouse model with or without castration was replicated.
The aim of castration was to remove the circulating an-
drogens, and the subcutaneous xenografts recurred at
3 weeks after castration, which reflected the state of pros-
tate cancer progression to CRPC. The LNCaP prostate
cancer cell line is androgen-dependent, and the expression
levels of AKR1C3 in LNCaP tumors at 3 weeks after cas-
tration were significantly increased compared to those of
the LNCaP sham tumors with MOD values of 0.081 ±
0.016 to 0.060 ± 0.018 (Figure 2A-C). These results indi-
cate that androgen ablation likely stimulates AKR1C3
gene activation and might be attributed to prostate cancer
progression.
The correlation of AKR1C3 expression with
clinicopathological features in prostate biopsy samples
In classical Partin tables, GS, PSA and age are key pa-
rameters for evaluating the progression of prostate can-
cer. The correlations of mean AKR1C3 expression with
GS, mean PSA and age were analyzed and delineated
(Tables 2 and 3). The data showed that AKR1C3 expres-
sion gradually increased with increasing GS, as indicated
by the MOD, exhibiting a positive correlation (rs = 0.396,
P = 0.025). PSA is considered to be a putative maker for
PCa progression and recurrence. The Spearman’s r values
for PSA with the GS or AKR1C3 were analyzed. Serum
PSA levels are not correlated with AKR1C3 (rs = −0.016,
P = 0.979) in BPH but are negatively correlated with
AKR1C3 expression (rs = −0.377, P = 0.036), which indi-
cates that AKR1C3 is a better marker to reflect the clini-
copathological stage and evaluation of PCa progression in
those patients with low levels of PSA.
Discussion
Androgens are known to play important roles in the
pathogenesis of PCa [15]. Recently, the intratumoral syn-
thesis of androgen from cholesterol or the conversion of
adrenal precursor androgens to active androgens repre-
sent two important mechanisms underlying the progres-
sion of PCa and CRPC [5,6,8,13]. Several studies have
indicated that AKR1C3 overexpression increases with
PCa progression through the mechanisms underlying
the key steroidogenic enzyme AKR1C3, which possesses
Figure 2 Immunohistochemical expression of AKR1C3 in LNCaP xenograft mouse models with or without castration. (A) LNCaP-sham.
(B) LNCaP + castration. (C) MOD of AKR1C3 in LNCaP xenograft mouse models. *P < 0.05, compared with sham group. Scale bar is 50 μm.
Figure 1 Immunohistochemical staining of AKR1C3 in human prostatic needle biopsies. (A) Normal prostate. (B) BPH. (C) PIN. (D) PBS
negative control of prostate cancer tissue. (E)-(H) Different GS prostate cancer tissues. (E) Gleason score = 6. (F) Gleason score = 7. (G) Gleason
score = 8. (H) Gleason score = 9. (I) The quantification bar for the MOD of AKR1C3. *P < 0.05, compared with BPH. #P < 0.05, compared with PIN.
Scale bar is 50 μm.
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Table 2 AKR1C3 expression and clinicopathological
features in PCa and BPH samples
Variables Cases of PCa BPH
GS = 6 GS = 7 GS = 8 GS = 9
Age (years) <60 2 2 0 3 3
61-75 6 4 6 4 5
>75 2 4 4 4 3
MOD of AKR1C3
<0.017 4 3 2 2 9
0.017-0.021 5 5 4 2 1
>0.021 1 2 4 6 0
Serum PSA <40 ng/ml 3 5 6 4 10
>40 ng/ml 7 5 4 6 0
Tian et al. Diagnostic Pathology 2014, 9:42 Page 5 of 6
http://www.diagnosticpathology.org/content/9/1/4217β-hydroxysteroid dehydrogenase type 5 (17β-HSD5)
activity, and PGF synthesis enzyme [13,16,17]. However,
the correlation between the quantification of AKR1C3
expression and the progression of PCa is unclear.
In our study, AKR1C3 expression was investigated by
immunohistochemical staining of prostate biopsy sec-
tions with different GSs. We found that AKR1C3 expres-
sion gradually increased with an elevated GS (rs = 0.396,
P = 0.025), implicating that AKR1C3 overexpression is
closely associated with PCa malignancy. Interestingly, the
distribution of AKR1C3 expression is different in PCa and
preneoplastic change. For BPH and PIN specimens, most
of the positive expression of AKR1C3 was observed in the
stromal cells other than the epithelial cells; however, a
gradually stronger positive staining of AKR1C3 was de-
tected in the epithelial cells for malignant PCa specimens
with GSs greater than 6. It is known that the epithelial
cells in normal prostate are dependent on stromal cells se-
creting EGF, fibroblast growth factor (FGF), nerve growth
factor (NGF) and IGF to support their growth and dif-
ferentiation [18]. During malignant transformation of
prostatic epithelial cells, androgen regulation shifts from
paracrine to autocrine and prostatic epithelial cells adap-
tively acquire the intratumoral androgen synthesis ability
to maintain the growth of tumor cells. It is reported that
AKR1C3 is a pivotal enzyme in converting Δ4-dione to
testosterone [13], 5α-DHT to 3α-diol [7], and androstene-
dione and dehydroepiandrosterone (DHEA) to intrapro-
static testosterone in the progression of PCa and CRPC.Table 3 Correlation of AKR1C3 expression with Gleason
score, PSA and age
Variable PCa BPH
GS PSA Age PSA Age
Spearman’s rho 0.396* −0.377* 0.169 −0.016 0.760*
AKR1C3 sig (double) 0.025 0.036 0.356 0.979 0.011
Number 40 40 40 10 10
*Spearman’s Rho test with significance of P < 0.05.Some studies showed that AKR1C3 has a preference in
prostate cancer for the androstenedione to DHT by an
alternative pathway [19]. Moreover, AKR1C3 possesses
11-ketoprostaglandin reductase activity and is capable
of converting PGD2 to 9α, 11β-PGF2α, which promotes
prostate cell proliferation through the PI3K/Akt signal-
ing pathway in androgen receptor-negative PCa [11,20].
These data indicate that overexpression of AKR1C3 is
the adaptive change that maintains tumor cell development
and progression, and the consistency of AKR1C3 expres-
sion with the GS and higher expression in LNCaP xeno-
grafts of castrated mice in our study further strengthen the
potential of AKR1C3 as a biomarker of PCa progression.
Recently, the potential prostate cancer biomarkers, such
as prostate cancer antigen 3 (PCA3), TMPRSS2-ERG gene
fusions and p501s (prostein), were investigated as auxiliary
diagnosis candidates for prostate cancer [21-24]. Previous
studies showed that poorly differentiated PCa tumors pro-
duced relatively little PSA and that PSA levels lost their
correlation with PCa aggressiveness [25-28]. Moreover, in
CRPC patients, the serum PSA levels are far behind the
progression of PCa [26-28]. In our retrospective study of
40 cases of PCa (GS ≥ 6, serum PSA > 4 ng/ml), the
AKR1C3 expression level exhibited a positive correlation
with the GS (score from 6 to 9) and a negative correlation
with PSA levels. Although the correlation index is low in
this study, the data still indicate that the expression of
AKR1C3 may serve as a promising biomarker for evaluat-
ing prostate cancer progression.
Conclusions
Overexpressed AKR1C3, as an adaptive response for the
progression of PCa, exhibited a positive correlation with
the GS. Our study shed light on the potential of AKR1C3
to serve as a promising biomarker for the progression
of PCa.
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